Assuntos
Anticorpos/análise , Discinesia Induzida por Medicamentos/imunologia , Glutamato Descarboxilase/imunologia , Esquizofrenia/enzimologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Fator Neurotrófico Derivado do Encéfalo/imunologia , Grupos Controle , Discinesia Induzida por Medicamentos/enzimologia , Humanos , Pessoa de Meia-Idade , Esquizofrenia/tratamento farmacológico , Esquizofrenia/imunologiaRESUMO
OBJECTIVE: Goal of our case control study was to establish the presence of antibodies to glutamic acid decarboxylase (GAD) in patients with chronic psychotic disorders. METHODS: Serum levels of GAD antibodies in 12 patients with chronic psychotic disorders (schizophrenia and schizoaffective disorders) and 10 age-matched healthy control subjects were evaluated utilizing enzyme linked immunosorbitent assay (ELISA). RESULTS: Antibodies to GAD in patients with chronic psychotic disorders have a higher mean than nonpatient control individuals. CONCLUSION: Our findings provide the first in-vivo evidence of positive GAD antibodies in chronic psychotic disorders and potentially may be used as a screening for these disorders.
RESUMO
Repetitive and stereotypic behavioral disturbances in patients with dementia are common; however, little is known regarding successful treatments. The authors describe six cases of elderly cognitively impaired patients exhibiting repetitive and stereotypic behaviors who were treated successfully with buspirone. The cases demonstrate that buspirone may be an effective and safe treatment for patients with dementia who demonstrate repetitive and stereotypic behavior disorders.
